Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,340 INR
Change Today -7.15 / -0.53%
Volume 1.3M
As of 7:05 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

aurobindo pharma ltd (ARBP) Snapshot

Open
1,340
Previous Close
1,348
Day High
1,359
Day Low
1,330
52 Week High
04/17/15 - 1,432
52 Week Low
05/27/14 - 612.00
Market Cap
391.4B
Average Volume 10 Days
998.4K
EPS TTM
40.27
Shares Outstanding
292.0M
EX-Date
02/16/15
P/E TM
33.3x
Dividend
2.00
Dividend Yield
0.39%
Current Stock Chart for AUROBINDO PHARMA LTD (ARBP)

Related News

No related news articles were found.

aurobindo pharma ltd (ARBP) Related Businessweek News

No Related Businessweek News Found

aurobindo pharma ltd (ARBP) Details

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and markets generic pharmaceuticals and active pharmaceutical ingredients in India, the United States, Europe, and internationally. The company offers generics formulations primarily in the therapeutic areas of cardiovascular system, central nervous system, antibacterials, cephalosporins, opthalmics, oral contraceptives, gastroenterologicals, NSAIDS, anti-fungal, anti-emetics, anti-virals, anti-diabetics, anti-allergic, antibiotics, anti-retrovirals, and others. The company was founded in 1986 and is headquartered in Hyderabad, India.

9,500 Employees
Last Reported Date: 08/1/14
Founded in 1986

aurobindo pharma ltd (ARBP) Top Compensated Officers

Managing Director and Director
Total Annual Compensation: 15.9M
Whole Time Director, Member of Corporate Soci...
Total Annual Compensation: 9.0M
Vice Chairman, Chairman of Corporate Social R...
Total Annual Compensation: 9.0M
Whole Time Director and Member of Shareholder...
Total Annual Compensation: 9.0M
Compensation as of Fiscal Year 2014.

aurobindo pharma ltd (ARBP) Key Developments

Aurobindo Pharma Submits Abbreviated New Drug Application for Dolutegravir 50mg

ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative Inc. (CHAI) announced that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment of HIV. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay (dolutegravir) for sale in the United States. Upon receiving Tentative Approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg through the President's Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014. This submission comes less than five years after ViiV Healthcare and CHAI signed an agreement to collaborate with the goal of bringing innovative formulations of medicines for the treatment and prevention of HIV/AIDS to people living with HIV in developing countries, on an affordable yet sustainable basis. CHAI and ViiV Healthcare worked together to identify a generic partner after conducting feasibility research. Following this initial joint work, ViiV Healthcare submitted necessary documentation to the FDA providing a selective waiver letter for the five-year period of New Chemical Entity (NCE) exclusivity that would have otherwise prevented FDA review and Tentative Approval of Aurobindo Pharma's ANDA at this time.

Aurobindo Pharma Limited Presents at 4th Edition of Global Pharma Regulatory Summit 2015, Apr-24-2015 03:00 PM

Aurobindo Pharma Limited Presents at 4th Edition of Global Pharma Regulatory Summit 2015, Apr-24-2015 03:00 PM. Venue: The Lalit, Sahar Airport Road, Mumbai - 400059, Maharashtra, India. Speakers: Nagendra Irukulapati, Head Regulatory ­ Emerging Markets.

Aurobindo Pharma Ltd. Appoints Avnit Bimal Singh as Additional Non-Executive, Independent Director

Aurobindo Pharma Ltd. has informed that the Board of Directors of the company vide Circular Resolution dated  March 25, 2015 have appointed Dr. (Mrs.) Avnit Bimal Singh as an Additional Director (Non-Executive, Independent) of the company, effective March 25, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARBP:IN 1,340.40 INR -7.15

ARBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $67.22 USD -0.15
Biocon Ltd 449.80 INR +1.70
Cipla Ltd/India 661.10 INR +2.05
Divi's Laboratories Ltd 1,825 INR -15.75
Shasun Pharmaceuticals Ltd 375.35 INR +1.50
View Industry Companies
 

Industry Analysis

ARBP

Industry Average

Valuation ARBP Industry Range
Price/Earnings 23.3x
Price/Sales 3.5x
Price/Book 8.5x
Price/Cash Flow 19.4x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUROBINDO PHARMA LTD, please visit www.aurobindo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.